Committee on Clinical Pharmacology and Pharmacogenomics

Leadership

Committee on Clinical Pharmacology and Pharmacogenomics

Peter O'Donnell, MD

Peter O'Donnell, MD

Chair, Professor of Medicine

Peter O’Donnell, MD is an Associate Professor of Medicine (Section of Hematology/Oncology), Chair of the Committee on Clinical Pharmacology and Pharmacogenomics.  He is the Associate Director of Clinical Implementation and Deputy Director for the Center for Personalized Therapeutics.  Dr. O’Donnell completed his Clinical Pharmacology and Pharmacogenomics training in 2010 and was board certified in Clinical Pharmacology in 2011. His research focuses on facilitating and understanding the delivery and adoption of pharmacogenomic information at the point-of-care to inform prescribing.

Telephone: 773-702-7564
E-mail: podonnel@medicine.bsd.uchicago.edu

Mark Ratain, MD

Mark Ratain, MD

Leon O. Jacobson Professor of Medicine

Mark Ratain, MD, Leon O. Jacobson Professor of Medicine; Director, Center for Personalized Therapeutics; Associate Director for Clinical Sciences, the University of Chicago Comprehensive Cancer Center; Chief Hospital Pharmacologist for the University of Chicago Medical Center

Dr. Ratain is a hematology/oncologist and clinical pharmacologist whose research activities include both pharmacogenetics and antineoplastic drug development. Interests include genetic and non-genetic factors affecting the therapeutic index of irinotecan, a drug active in colorectal cancer and other solid tumors, factors affecting the therapeutic index of epidermal growth factor receptor inhibitors, genetic variation in glucuronosyltransferases, and methodological issues relevant to anticancer drug development.

Telephone: 773-795-5453
E-mail: mratain@medicine.bsd.uchicago.edu

Mark Applebaum, MD

Mark Applebaum, MD

Associate Professor of PediatricsCommittee on Cancer Biology | Committee on Clinical Pharmacology and Pharmacogenomics

Dr. Applebaum focuses his research on how specific epigenetic marks can identify patients with aggressive neuroblastoma that may benefit from alternatives to standard therapy. His laboratory is also identifying how the low-oxygen environment of tumors makes cancer cells more resistant to standard therapies by inducing changes in these same epigenetic marks. Identifying the genes and cellular pathways responsible for these changes may ultimately open new avenues for novel therapeutic options.


Telephone:
773-834-8429
E-mail: applebaumm@uchicago.edu

Lexi nash smith

Lexi nash smith

Program Administrator | Committee on Clinical Pharmacology and Pharmacogenomics

Telephone: 773-834-8429
E-mail: lexis@bsd.uchicago.edu

Comprehensive training to launch your career in clinical pharmacology and pharmacogenomics.

Comprehensive training to launch your career in clinical pharmacology and pharmacogenomics.

Application Inquiries

lexis@bsd.uchicago.edu

Phone

773-834-8429

Open Hours

Mon – Fri. 9:00 – 4:00

Address

5841 S. Maryland Ave, MC 2115
Chicago, IL 60637